MINI FUTURE LONG - ELI LILLY & CO | Real-time Euronext Paris 01:31:46 27/06/2024 pm IST | ||
| 6.413 EUR | +0.20% |
|
| Current month | +35.91% | ||
| 1 month | +38.83% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 27/24/27 | 6.413 | +0.20% |
| 26/24/26 | 6.4 | +1.19% |
| 25/24/25 | 6.325 | +0.60% |
| 24/24/24 | 6.287 | +3.85% |
| 21/24/21 | 6.054 | -2.02% |
Real-time Euronext Paris
Last update June 27, 2024 at 01:31 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| ZK5NB | |
| ISIN | NLBNPNL2OR43 |
| Date issued | 13/03/2024 |
| Strike | 564 $ |
| Maturity | Unlimited |
| Parity | 50 : 1 |
| Emission price | 3.37 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.57 € |
|---|---|
| Lowest since issue | 3.06 € |
| Spread | 0.199 € |
| Spread % | 3.06% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
901.3
USD
Average target price
860.5
USD
Spread / Average Target
-4.52%
- Stock Market
- Certificates
- ZK5NB Certificat
